CClinicalTrials.gg
CompletedNCT05158192Updated Feb 14, 2022

Bioavailability of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to Reference Product

A Phase 1 interventional study of Diosmin/Hesperidin (90/10) 500 mg Test Drug and Diosmin/Hesperidin (90/10) 500 mg Reference Product in Bioequivalence, sponsored by Laboratorios Andromaco S.A.. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by Laboratorios Andromaco S.A. · Phase 1, Interventional, and Basic science

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This Pilot study investigated the bioavailability in adult human subjects of 1 tablet formulations containing Diosmin/Hesperidin (90/10) 500 mg. The Pilot study was performed at a single site with 12 subjects. Participants took 1 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There was a washout of 7 days between each study period.

Read the detailed description

The primary objective of the study is to investigate the relative bioavailability of

Diosmin/Hesperidin (90/10) of 1 tablet formulations with Diosmin/Hesperidin (90/10) 500 mg to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

  • Test Product: Product manufactured by Laboratorios Andrómaco S.A.
  • Reference Product: Daflon [Trademark], product of Les Laboratoires Servier, France.

The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters area under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to infinite (AUC0-inf), and maximum plasma concentration (Cmax) for total metabolite Diosmetin and Hesperetin was determined. Participants were confined in the study site for approximately 42 hours during each study period (for 10 hours pre-dosing and for 32 hours post dosing) during which pharmacokinetic (PK) blood samples were obtained. 21 blood samples were taken up to 32 hours after the administration in each period. Participants returned to the site to provide additional blood samples at 48 h, and 72 h postdose. The washout period between the two study periods was 7days. The samples from each participant were analyzed with validated LC-MS/MS method used for estimation of Diosmetin and Hesperetin in plasma.

The safety objective was to evaluate the tolerability of both formulations in subjects by collecting adverse events.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Laboratorios Andromaco S.A. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy male and/or non-pregnant, non-breast feeding female literate volunteers of 18 to 45 years (both years inclusive) with BMI of 18.50 - 29.99 Kg/m2 and weight > 50 Kg.
  2. Healthy volunteers as evaluated by medical history, vitals and general clinical examination.
  3. Normal or clinically insignificant biochemical, hematological, urine and serology parameters.
  4. Normal or clinically insignificant ECG.
  5. Negative urine test for drugs of abuse for both males and females and negative pregnancy test for females and do not plan to become pregnant during course of the study and for 03 months after completion of study.
  6. Volunteers who are willing to use acceptable methods of contraception (barrier method/IUD/surgical) or abstinence, for the entire duration of the study and do not plan to be pregnant for atleast 1 month after the last drug administration.
  7. Volunteers who can give written informed consent and communicate effectively.

Exclusion criteria

Exclusion Criteria:

  1. History of any major surgical procedure in the past 03 months.
  2. History of any clinically significant cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders.
  3. History of chronic alcoholism/ chronic smoking/ drug of abuse.
  4. Volunteers with known hypersensitivity to Diosmin/Hesperidin or any of the excipients.
  5. History of consumption of tobacco containing products within 48 hours prior to proposed time of dosing
  6. Volunteers who are positive for hepatitis B surface antigen, anti-hepatitis C antibody, treponemal antibodies and human immunodeficiency virus (HIV 1\&2) antibodies.
  7. Present or past history of intake of drugs or any prescription drug or over the counter (OTC) drugs within 14 days which potentially modify kinetics / dynamics of Diosmin/Hesperidin or any other medication judged to be clinically significant by the investigator.
  8. History of consumption of grapefruit and/or its products within 10 days prior to the start of study.
  9. Volunteers who had participated in any other clinical study or who had bled during the last 03 months before check-in.
  10. History of consumption of one or more of the below, 48 hours prior to dosing: Xanthine containing food or drinks such as cola, chocolate, coffee or tea, citrus fruits or items (lime, lemon and orange), alcohol and any other food/beverage known to have interactions as deemed by the investigator
  11. Volunteers who are dysphagic.
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Diosmin/Hesperidin (90/10) Test Product

    Participants received one tablet of the test formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.

    Drug: Diosmin/Hesperidin (90/10) 500 mg Test Drug

  • Active comparator
    Diosmin/Hesperidin (90/10) Reference Product

    Participants received one tablet of the marketed reference formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.

    Drug: Diosmin/Hesperidin (90/10) 500 mg Reference Product

Interventions

  • DrugDiosmin/Hesperidin (90/10) 500 mg Test Drug

    Investigational Medicinal Product

  • DrugDiosmin/Hesperidin (90/10) 500 mg Reference Product

    Daflon (Trademark)

06

What researchers measure

Primary outcomes

  1. Total Diosmin/Hesperidin (90/10): area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)

    23 samples up to 72 hours will be taken after the administration in each period.

    Time frame: From tablet intake and up to 72 hours after tablet intake

  2. Total Diosmin/Hesperidin (90/10): area under the plasma concentration-time curve from 0 to t hours (AUC0-t)

    23 samples up to 72 hours will be taken after the administration in each period.

    Time frame: From tablet intake and up to 72 hours after tablet intake

  3. Total Diosmin/Hesperidin (90/10): Maximum plasma concentration (Cmax)

    23 samples up to 72 hours will be taken after the administration in each period.

    Time frame: From tablet intake and up to 72 hours after tablet intake

07

Study locations

1 site
  • Azidus Laboratories Ltd.
    Chennai, Tamil Nadu 600048, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05158192
Lead sponsor
Laboratorios Andromaco S.A.
Responsible party
Sponsor
First posted
Dec 15, 2021
Start date
Nov 4, 2021
Primary completion
Dec 14, 2021
Completion
Dec 14, 2021
Last update
Feb 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion